Omniscope

Omniscope is founded in 2020 by Vijay Vaswani, Holger Heyn and Lynette Ang with operations in Barcelona, Spain. Omniscope aims to make healthcare more accessible by leveraging the power of immune cell sequencing and artificial intelligence. The company focuses on the adaptive immune system, particularly T cells, which are key players in fighting diseases like cancer, infections, and autoimmune disorders. Their technology analyzes T cell receptors (TCRs) to identify unique immune signatures—cracking the immune code. This allows them to pinpoint specific T cell clones linked to disease progression or treatment response. Omniscope combines high-throughput sequencing with AI-driven analytics, making it scalable and precise. The company is targeting big challenges in oncology, immunotherapy, and diagnostics—improving early cancer detection or predicting immunotherapy outcomes.

Co-founders: Vijay Vaswani (CEO), Holger Heyn and Lynette Ang

‍